April 24, 2020 / 12:32 AM / a month ago

BRIEF-Mesoblast Announces 83% Survival In COVID-19 Patients With ARDS Treated With Remestemcel-L

April 24 (Reuters) - Mesoblast Ltd:

* 83% SURVIVAL IN COVID-19 PATIENTS WITH MODERATE/SEVERE ACUTE RESPIRATORY DISTRESS SYNDROME TREATED WITH CO'S CELL THERAPY REMESTEMCEL-L Source text reut.rs/351jWJX Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below